(Date:5/16/2008)...s gain benefit from calcitriol, an oral form , ... activated vitamin D may cut the risk of death for...ease by about one quarter, a new study suggests. ...tients, those being treated with calcitriol, an or...risk of death lowered by 26 percent when compared ...
(Date:5/16/2008)... Frail Seniors and People With,Disabilities, OAKL...usands of,homecare workers across the state are ou...ts to hours of service, wages and benefits,which ...orkers and the,people they serve deeper into pover...seniors and people with disabilities from Schwarze...
(Date:5/16/2008)...National HIV Vaccine Awareness Day, May,18, WASHI...x years into the,AIDS epidemic, someone is newly i...unday, May 18, HIV Vaccine Awareness Day, AIDS Act... Institute of Allergy and Infectious,Disease (NIAI...s everyone,to help end the AIDS epidemic by partic...
(Date:5/16/2008)...untsworth plc (LSE: HNT), "the Group",a leading i...nications,group headquartered in London, released ...Group,s performance in the first quarter 2008 (the...follows below., 15 May 2008, ...erim Management Statement, Record net ...
Breaking Medicine News(10 mins):Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4...the cause of 90 percent of the world’s lung cancer...mber of cigarettes they smoke per day are exposed ...r cancer-causing agent. However, the reduction in ...n exposure is often temporary and not proportional...
...ey have found a gene that predisposes people to be... // involving 262 families with alcoholic members ...romosome 15 that had previously been linked to alc...s -- GABRG3 -- did appear to influence alcoholism ...
...he abilities required for success in school are si...ce.// The idea that one’s cognitive abilities pre...l world has been controversial. Many people believ...t than what is need for academic success. Scientis...
...acement surgery has been the only treatment for a ...r some younger patients may replace the traditiona...l’s golf team. But a broken hip in grade school le...Decreased blood flow caused his hip joint to die. ...
Other Medicine News:Health News:Reducing Number Of Cigarettes Not Enough 2(Date:5/15/2008)...y Remains for an Antiplatelet Therapy that, Combin...mbination of Plavix/Iscover and Aspirin, Accor...THAM, Mass., May 15 /- Decision Resou...sory firms for pharmaceutical and,healthcare issue...ffers,improvement in patient compared to Sanofi-Av...
(Date:5/15/2008)...d soon after CEA Trial data reports in third quart...ISCO, May 15 /- VIA Pharmac...ompany focused on the development of,compounds for...d today that,it has completed patient enrollment i... study is one of three Phase 2 trials investigatin...
(Date:5/15/2008)...the 21st Annual Meeting of The American Society of...Meeting -, IRVINE, Calif., May 15 /PRNewswire-Fir... IDMI ) today announced the presentation of updat...ting mifamurtide (L-MTP-PE) in,patients with lung ...sarcoma, a rare and often fatal bone tumor that ty...
(Date:5/14/2008)..., May 14 /- Progen,Pharmace...unced that the,Company has resumed patient enrolme...ently acquired polyamine analogue, PG-11047 (forme... Progen has commenced development of PG-11047 - t...ne program - following its acquisition of,Cellgate...
Breaking Medicine Technology:Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 1Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 2Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 3Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 4Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 5Author Kris Carr to Sign Crazy Sexy Cancer Tips at Two Borders 28R 29 Stores in California 664 1Author Kris Carr to Sign Crazy Sexy Cancer Tips at Two Borders 28R 29 Stores in California 664 2Youth Drug Use at a Five Year Low New Survey Shows 662 1Youth Drug Use at a Five Year Low New Survey Shows 662 2Youth Drug Use at a Five Year Low New Survey Shows 662 3Dr Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance 660 1Dr Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance 660 2...ESS WIRE)--May 7, 2007 - Alnylam,Pharmaceuticals, ...ompany, presented data from its experimental infec...s, (PAS) Annual Meeting being,held in Toronto. Thi...ompany,s clinical development program for ALN-RSV0...atory syncytial virus (RSV),infection. Results dem...
...ncing AT-1001 into Later Stage Clinical,Trials, BA...utics,Corporation today announced preliminary resu...in subjects with Celiac Disease (CD), an,autoimmun...nited,States. Alba,s study, the first Phase IIa tr...nts for AT-1001 in CD, was designed to,evaluate th...
Other Medicine Technology:Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus 2Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus 3Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus 4Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus 5Alba Therapeutics Corporation Reports Preliminary Phase IIa,Clinical Trial Results for AT-1001 for the Treatment of Celiac,Disease 2Alba Therapeutics Corporation Reports Preliminary Phase IIa,Clinical Trial Results for AT-1001 for the Treatment of Celiac,Disease 3...ing with wireless connectivity, ,The wireless fun...toring system that makes it possible to connect S/...ation via Wireless LAN technology., ,Wireless ope...entralized surveillance within the care unit. It a...
...onitoring, ,The Deltatrac II is a complete metabo.... It's ideal for use with a ventilator or a canopy...hing and mechanically ventilated patients of all a...ally ill patients vary extremely; both overfeeding...
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces.
For accurately monitoring core temperature and heart and breath sounds.
Medicine Products: